US Health Secretary Kennedy says HHS to launch campaign to encourage wearable devices

Published 06/24/2025, 04:03 PM
Updated 06/24/2025, 06:05 PM
© Reuters. U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. speaks as he attends a press conference with Centers for Medicare and Medicaid Services Administrator Mehmet Oz to discuss health insurance reform, at the Department of Health and Human

By Puyaan Singh

(Reuters) -U.S. Health Secretary Robert F. Kennedy Jr. said on Tuesday that the Department of Health and Human Services plans to launch an advertising campaign to encourage Americans to adopt wearable devices, such as those that measure heart rate or blood glucose levels.

Shares of continuous glucose-monitoring device makers Abbott and Dexcom (NASDAQ:DXCM) were up 3.6% and 10%, respectively, in afternoon trading.

"We think that wearables are a key to the MAHA agenda, Making America Healthy Again ... my vision is that every American is wearing a wearable within four years," Kennedy said, speaking before the U.S. House of Representatives Committee on Energy and Commerce’s Subcommittee on Health during a hearing on his department’s 2026 budget request.

"It’s a way of people can take control over their own health ... they can see what food is doing to their glucose levels, their heart rates and a number of other metrics as they eat it," he added.

Kennedy also described the campaign as "one of the biggest" in the agency’s history.

Kennedy, who has long promoted healthy eating over medicine as a way to combat obesity and has been a prominent critic of vaccine safety, has also been critical about Novo Nordisk (NYSE:NVO)’s diabetes drug Ozempic, which is often prescribed for weight loss.

However, he has expressed support for prescription of such weight-loss drugs for adults with morbid obesity and diabetes, provided it is accompanied by exercise.

"You know the Ozempic is costing $1300 a month, if you can achieve the same thing with an $80 wearable, it’s a lot better for the American people," Kennedy said, adding, "We’re exploring ways of making sure that those costs can be paid for."

J.P.Morgan analyst Robbie Marcus commented, "We think it’s premature to interpret this as a direct comment on whether Medicare and other commercial payors will move towards covering non-intensive Type II diabetes patients or other areas of proactive monitoring."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.